Crossmark

Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway

Published Online: 2020-12-01

Published Print: 2020-12

Authors

Ng, Benjamin http://orcid.org/0000-0001-8970-0932
Cook, Stuart A.

Schafer, Sebastian
License Information

Text and Data Mining valid from 2020-12-01

Version of Record valid from 2020-12-01
More Information

Article History

Received: 15 July 2020

Revised: 23 September 2020

Accepted: 25 September 2020

First Online: 1 December 2020

Conflict of interest

: S. A. Cook and S. Schafer are coinventors of the patent applications (WO2017103108, WO2017103108 A2, WO 2018/109174 A2, and WO 2018/109170 A2) for “Treatment of fibrosis”. S. A. Cook and S. Schafer are coinventors of the patent applications (GB1900811.9, GB 1902419.9, and GB1906597.8) for “Treatment of hepatotoxicity, nephrotoxicity, and metabolic diseases”. B. Ng, S. A. Cook, and S. Schafer are coinventors of the patent application (WO/2019/073057) for “Treatment of SMC mediated disease”. S. A. Cook and S. Schafer are cofounders and shareholders of Enleofen Bio Pte. Ltd., a company that develops anti-IL11 therapeutics.

Document is current